New hope for rare lung cancer: targeted drug trial launches

NCT ID NCT07336732

Recruiting now Disease control Sponsor: Avistone Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called andamertinib, alone or with chemotherapy, against standard chemotherapy in people with advanced non-squamous lung cancer that has unusual EGFR mutations. About 40 participants who have not had prior treatment will be enrolled. The goal is to see if the drug is safe and works better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Andamertinib (a targeted drug) with or without platinum-based chemotherapy
What this could lead to: If successful, this could provide a new treatment option for people with a rare type of lung cancer that has limited targeted therapies.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes over standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.